TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05268042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderately carbohydrate-restricted diet
Description: For this study, the investigators will use the low glycemic, moderately carbohydrate-restricted diet that the investigators have previously shown is associated with depletion of hepatic lipid content, and improvement in insulin resistance in adolescents with NAFLD. This diet has a macronutrient composition of approximately 25% energy from carbohydrate, 20% energy from protein, and 55% energy from fat. No food group is excluded in this diet prescription; however, the diet emphasizes low-glycemic sources of carbohydrate, and includes mainly whole foods (vegetables, fruits, whole grains) with minimal highly processed grain products and added sugar. Protein foods will include meat, poultry, fish, eggs, and whey protein supplements if necessary. Fat-containing foods will include olive, coconut, and nut oils; butter; tree nuts and nut butters; cheese; cream; coconut milk; avocados; and the fat found in meat. A number of full-fat dairy products will be included.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fat-restricted diet
Description: The fat-restricted, control diet will consist of approximately 60% carbohydrate, 20% protein, 20% fat. Participants will be given low-fat foods, whole-grain foods, fruits, and vegetables. The meal plans will minimize cholesterol, high-fat foods, high-cholesterol foods, processed starches, and added sugar, and will provide \<2300 mg/day sodium. Saturated fat will be limited to 10% of total fat intake, and all dairy products will be fat-free (or low fat).
Study: NCT05586230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Administered orally based on participant's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Administered orally based on participant's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Administered orally based on participant's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Administered orally based on participant's weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB
Description: Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB
Description: Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB
Description: Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized background regimen (OBR) for multidrug-resistant TB (MDR-TB
Description: Non-study prescribed OBR will vary according to local, national and/or international guidelines for treatment of children with MDR-TB. Administered in addition to single dose of Pa.
Study: NCT05765799

Intervention type: OTHER
Intervention: Questionary
Description: Questionary will be administrated to evaluated the information for patients on interventional radiology (dedicated consultation, information posters, explanatory video, information form, etc.).
Study: NCT05488717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: art-based mandala application
Description: Patients who are routinely scheduled for bone marrow transplantation are admitted to the unit one week before the transplant and treatment is started and transplantation is performed a week later. All patients in the intervention and control group will be filled out forms upon hospitalization after receiving their informed consent at the beginning of the study. Subsequently, patients in the intervention group will be given art-based mandala painting, which is sampled below, for 30 minutes for a week, accompanied by instrumental music featuring natural sounds in a room with light-heat control. Mandala painting templates and crayons will be provided by the researcher. The researcher will not intervene in any way other than time management during the preparation and painting of the environment. The researcher participated in training on art-based mandala and made preliminary preparations.~No intervention will be made to the control group except for routine clinical applications.
Study: NCT06734871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR T cells
Description: chimeric antigen receptor T cells
Study: NCT06758947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 MG
Description: oral tablet upadacitinib

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cellcept Oral Product
Description: active control group 2000mg MMF daily
Study: NCT06319079

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified powder milk
Description: Super 1.000 Mamá It's made up of milk with added vegetable oils, fish oil, carbohydrates from corn, prebiotic fiber (inulin), vitamins, and minerals, with specifically defined proportions. It has medium energy content, is balanced in protein, fats, and carbohydrates, and provides a significant content of both polyunsaturated fatty acids, such as omega-6, and omega-3, and the added docosahexaenoic acid, as recommended by international organizations. The reconstituted 200 ml serving delivers between 20 and 40% of the Daily Reference Intake in critical nutrients for this particular group of people, which include minerals such as calcium, iron, zinc, iodine, and vitamins such as A, D, C, B12 and folic acid. The rest of the vitamins, and minerals are also at the same level, allowing those who consume it to incorporate a large amount of nutrients regularly. Addvance SA, an SME dairy company from the Province of Santa Fe, will carry out the production of this milk.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Powder milk
Description: Commercial powder milk constitutes dehydrated commercially available cow's milk, which is fortified with Vitamins A and D by law.
Study: NCT06453525

Intervention type: OTHER
Intervention: intubation
Description: Tracheal intubation using one of the three existing videolaryngoscopes

Intervention type: OTHER
Intervention: intubation
Description: Tracheal intubation using one of the three existing videolaryngoscopes

Intervention type: OTHER
Intervention: intubation
Description: Tracheal intubation using one of the three existing videolaryngoscopes
Study: NCT06549023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-session panretinal PRP (SS-PRP)
Description: Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas in one comprehensive session, typically delivered in a single clinical visit.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple-session panretinal PRP (MS-PRP)
Description: Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas over two separate visits with at least one week apart.
Study: NCT06350617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency, ipsilateral M1
Description: rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: ipsilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Frequency, bilateral M1
Description: rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Frequency, Lt. DLPFC
Description: rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: Lt. DLPFC~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Frequency, bilateral M1
Description: rTMS intervention: 20 sessions of 10-Hz rTMS at 90% resting motor threshold (RMT), 50 pulses per session with a 25-second interval between sessions, totaling 1,000 pulses.~rTMS target: bilateral primary motor cortex of lower extremity.~Total rTMS sessions: once a day, 5 days per 2 weeks, for 4 weeks, totaling 10 sessions.~Additional treatment: Treadmill gait training after the intervention, as well as the routine pharmacotherapy based on the guidelines for management of patients with Parkinson's disease.
Study: NCT05459662

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oat based porridge
Description: Consume one preparation per day, orally

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: plant based preparation
Description: Consume one preparation per day, orally
Study: NCT06407687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro Dry Needlig
Description: Electro Dry Needling is a modified form of dry needling which utilises an electro-stimulation unit connected via cables to fine filament needles. The combination of dry needling with electro-stimulation often prolongs the pain relief effect by blocking nerve pathways and preventing pain signals from travelling to the brain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dry needling
Description: Dry needling is a technique that acupuncturists, physical therapists and other trained healthcare providers use to treat musculoskeletal pain and movement issues.
Study: NCT05029544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic taping
Description: The intervention of this experimental study was therapeutic taping (dynamic tape) on the symptomatic shoulders of the participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping
Description: The intervention of this experimental study was therapeutic taping (kinesio tape) on the symptomatic shoulders of the participants.

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy and Rehabilitation
Description: exercise, manuel therapy, mobilization, massage, sensorimotor control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and Rehabilitation
Description: exercise, manuel therapy, mobilization, massage, sensorimotor control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy and Rehabilitation
Description: exercise, manuel therapy, mobilization, massage, sensorimotor control
Study: NCT05573672

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dietary Counselling combined with Omega-3 Supplementation
Description: Dietary Counselling: Seven, bi-weekly counselling sessions over 12-weeks conducted by a licensed Naturopathic Doctor. Each session will be 45-60 minutes in length. The recommendations will be based on the Mediterranean diet and the results of a recent scoping review which summarized the research related to diet and anxiety. The intervention will include motivational interviewing, mindful eating techniques, goal setting and action planning. A range of resources related to meal planning, recipes, cooking education, shopping lists and tracking sheets will be provided in an individualized manner.~Dietary Supplement: AquaOmega High EPA Omega-3 capsules will be taken at a dose of four capsules, once daily (containing a total of 3456 mg of omega-3 fatty acids: 2659mg of Eicosapentaenoic acid (EPA), 532mg of docosahexaenoic acid (DHA), and 800IU of Vitamin D), with a meal.
Study: NCT06555055

Intervention type: OTHER
Intervention: CT trochlear thickness change
Description: Preoperative and postoperative CT scan measuring trochlear thickness of PFJ was defined as distance from deepest part of trochlea and line tangential to the anterior aspect of the femoral cortex. It was assessed on the sagittal cuts.~CT images will be viewed using Sante DICOM viewer version 5.4.2 and image fusion will be done using Overlay multiple image software.~Two observers will measure the angles and the intraobserver and interobserver reliabilities will be assessed for consistency by the intraclass correlation coefficient (ICC) and reliability coefficient using the SPSS software
Study: NCT06184867

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Relational Agent
Description: Alex was developed as an interactive and personalized education and decision support intervention for smart devices, and guides participants through the key primary stages of assessing personal risk of hereditary cancer, providing genetic education, cancer family tree, patient testimonials, asks and answers questions and for those who choose, facilitates genetic testing, and streamlines disclosure of test results.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Letter
Description: Letter will be signed by Dr. Toppmeyer and contain a recommendation to contact the Life Center for a cancer genetic risk assessment and to consider GT.
Study: NCT05598879

Intervention type: OTHER
Intervention: anonymized data collection during programmed surveillance clinical follow up
Description: anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform

Intervention type: OTHER
Intervention: anonymized data collection during programmed surveillance clinical follow up
Description: anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform

Intervention type: OTHER
Intervention: anonymized data collection during programmed surveillance clinical follow up
Description: anonymized data entry of demographic, clinical, imaging, laboratory, cancer treatment, and cardiovascular events into a RedCap Cloud platform
Study: NCT05035199

Intervention type: BEHAVIORAL
Intervention: Spiritual Distress and Resources Questionnaire (SDRQ)
Description: The SDRQ is a validated self-rating instrument to assess spiritual distress and resources. It focuses on beliefs, attitudes, experiences and practices of various kinds (every day and extraordinary), as well as on (dis-)connectedness. It consists of 22 items covering three subscales: spiritual resources, spiritual distress, and spiritual coping (Peng-Keller et. al., 2020, submitted). We constructed five additional questions to find out more why patients want to include spiritual aspects in their treatment.
Study: NCT04948151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Patients will apply 2-gram applications up to 9 times per month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will apply 2-gram applications up to 9 times per month
Study: NCT05381571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivating reminiscence physical therapy
Description: The jDome BikeAround system involves participants using a stationary bike while their selected location is displayed in front of them on a domed projector screen using Google Street View. Using pedals on the bike they can propel themselves down the street, steer and change direction as they wish.
Study: NCT06002542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information provided
Description: get information at every stage of care in emergency room

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Information is only provided when participants request it.
Study: NCT05053009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brufen Retard
Description: 800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brufen Retard
Description: 800 mg tablet of Brufen Retard will be adminstered orally one hour before local anesthesia
Study: NCT05735444

Intervention type: DEVICE
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure (CPAP) is one of the standard medical treatments for patients with OSAS. The mechanism of CPAP probably involves maintenance of a positive pharyngeal transmural pressure so that the intraluminal pressure exceeds the surrounding pressure. CPAP also increases end-expiratory lung volume, which stabilises the upper airway through caudal traction.
Study: NCT04462107

Intervention type: OTHER
Intervention: Surveys
Description: All participants will complete surveys that range in time from baseline to 3 months post partum.
Study: NCT04688268

Intervention type: DRUG
Intervention: deep neuromuscular blockade
Description: Train of Four=0/4, Post tetanic count 1-2
Study: NCT04323748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituxan
Description: The dose dense administration of rituximab will consist of 5 doses total~Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2
Study: NCT05300100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sensorimotor activities
Description: The activities chosen involve either the whole body or specific parts such as the hand to grasp or perform graphic tests.~* Trial 1 : Straightening: passage from sitting to sitting.~* Trial 2 : Movement with difficulty of balance: heel-toe walking~* Trial 3 : Movement with difficulty of balance with a structured visual environment: heel-toe walk in a contrasting fabric decoration to increase the impact of visual flow~* Trial 4 : Move to a target, 5 m away~* Trial 5 : Graphics: drawing of a tree. This test requires spatial skills and the establishment of median space in written transcription.~* Trial 6 : Manual entry: collection of 12 small cubes arranged in an arc in front of the child using one hand, the choice of which will be left to the child.~All of these tests will be offered according to a so-called interlaced protocol, that is to say, each execution of an action will be followed by an action simulation, and this alternation will be repeated 5 times for each task. .
Study: NCT04786873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macimorelin
Description: Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macimorelin
Description: Dosage form: granules for oral solution, Dosage: 1.0 mg/kg body weight, Frequency and duration: single oral dose administration. Macimorelin will be supplied in single-use aluminum pouches (synonymous: sachets) each containing 63.6 mg macimorelin as acetate, which provide 0.5 mg/mL of macimorelin when dissolved in 120 mL of water. The excess amount of 3.6 mg represents an overfill, which is needed to obtain the target concentration.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: For the arginine GHST, R-Gene® 10 from Pfizer will be provided as labelled investigational medicinal product (IMP). After an overnight fast, soluble arginine hydrochloride (0.5 g/kg) will be given i.v. as an infusion with an infusion duration of 30 min.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Arginine
Description: For the arginine GHST, R-Gene® 10 from Pfizer will be provided as labelled investigational medicinal product (IMP). After an overnight fast, soluble arginine hydrochloride (0.5 g/kg) will be given i.v. as an infusion with an infusion duration of 30 min.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: For the clonidine GHST, CATAPRESAN® 75 tablets (Boehringer Ingelheim) will be provided as labelled IMP. Each tablet contains 75 ug clonidine hydrochloride. The tablets will be provided in boxes containing 10 tablets. The target dose is 0.15 mg/m2 body surface with a dose range of 0.08 - 0.15 mg/m2. Maximum dose will be 0.25 mg.~After an overnight fast, clonidine (0.15 mg/m2 body surface) will be given orally.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: For the clonidine GHST, CATAPRESAN® 75 tablets (Boehringer Ingelheim) will be provided as labelled IMP. Each tablet contains 75 ug clonidine hydrochloride. The tablets will be provided in boxes containing 10 tablets. The target dose is 0.15 mg/m2 body surface with a dose range of 0.08 - 0.15 mg/m2. Maximum dose will be 0.25 mg.~After an overnight fast, clonidine (0.15 mg/m2 body surface) will be given orally.
Study: NCT05701969

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study: NCT04261387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUT014 Gel
Description: Topical application qd for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for LUT014 Gel
Description: Matching placebo for qd topical application for 28 days
Study: NCT05465603

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ETDNO (Elastic Tension digital neoprene orthosis)
Description: A bespoke orthosis created from neoprene.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETDNO (Elastic Tension digital neoprene orthosis)
Description: A bespoke orthosis created from neoprene.
Study: NCT06519006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise
Description: Exercises aimed at this issue consist of identification and isolated contraction of the pelvic floor muscles as well as their activation during complex movements and daily activities. During the engagement of the pelvic floor muscles, the correct engagement of the respiratory activity is important. Within the exercise units, exercises are used from sphincter contraction, through the gradual activation of individual pelvic floor layers in various ways, to their complex involvement in movement activities. Exercises are practiced repeatedly, at different frequencies and intensities that gradually increase, 4-5 times per day.